Short answer
JAK2 mutation testing is used in the workup of myeloproliferative neoplasms, a group of bone marrow disorders that can raise red cells, platelets, or white cells and increase clotting risk. It may come up after unexplained clots, especially unusual-site clots, when CBC patterns such as high hematocrit or high platelets suggest polycythemia vera, essential thrombocythemia, or related conditions.
When JAK2 testing may fit
| Clue | Why it matters | Common follow-up |
|---|---|---|
| High hematocrit or hemoglobin | Can fit polycythemia vera in the right context. | JAK2 testing, EPO level, oxygen/smoking context, hematology review. |
| High platelets | Can fit essential thrombocythemia, but many reactive causes exist. | Iron studies, inflammation context, JAK2/CALR/MPL testing if persistent. |
| Unusual-site thrombosis | May prompt evaluation for MPN or APS depending on context. | CBC trend, JAK2 testing, APS testing, specialist review. |
What a positive result means
A positive JAK2 result supports a clonal blood-cell disorder in the right setting, but diagnosis may still require CBC trends, bone marrow evaluation, and exclusion of reactive causes. JAK2 V617F is the most common MPN mutation, but exon 12 testing can matter in some polycythemia vera cases.
What a negative result means
A negative JAK2 result does not rule out every MPN or every clotting disorder. CALR and MPL can still be relevant, especially when platelets are high, and BCR-ABL1 matters when the CBC pattern points toward CML rather than a JAK2-driven MPN.
Common follow-up tests
| Follow-up | Why it is ordered |
|---|---|
| Erythropoietin (EPO) | Helps distinguish some secondary causes of erythrocytosis from PV. |
| Iron studies | Iron deficiency can complicate interpretation of high platelets or a masked PV picture. |
| CALR/MPL testing | Often used when JAK2 is negative but thrombocytosis or MPN suspicion remains. |
| BCR-ABL1 testing | Used when the pattern suggests CML rather than a classic BCR-ABL1-negative MPN. |
Questions to ask
- Was JAK2 ordered because of a clot, high hematocrit, high platelets, high white count, or spleen enlargement?
- Were CBC trends persistent or only abnormal during acute illness?
- If JAK2 is negative, should CALR, MPL, BCR-ABL1, EPO, iron studies, or bone marrow testing be considered?
- Should APS or inherited thrombophilia testing be considered separately?
Related guides: CBC blood test, CALR and MPL testing for MPNs, BCR-ABL1 testing for CML, and antiphospholipid syndrome antibody testing.
FAQ
Does a positive JAK2 result mean I have cancer?
It suggests a clonal myeloid disorder may be present, but the exact diagnosis still depends on the CBC pattern, symptoms, bone marrow findings, and the rest of the workup.
Can JAK2 be used as a general clot screen?
No. It is most useful when the blood counts or clot location make an MPN plausible.
What if JAK2 is negative but the platelets are still high?
CALR, MPL, iron studies, inflammation, and bone marrow evaluation may still matter depending on the pattern.
What if the hematocrit is high but JAK2 is negative?
Secondary causes of erythrocytosis should be reviewed, and exon 12 or broader MPN testing may be considered in the right setting.
Is JAK2 inherited from a parent?
Usually not. The common MPN-associated JAK2 changes are somatic, meaning they are acquired in blood-forming cells.
Should I also have APS or inherited thrombophilia testing?
Sometimes, but they answer different questions. The right choice depends on the clot pattern, CBC findings, age, and family history.